Nadorameran

Drug Profile

Nadorameran

Alternative Names: CV-7201; RNActive® rabies vaccines - CureVac

Latest Information Update: 17 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CureVac
  • Class RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Rabies

Most Recent Events

  • 26 Jul 2017 CureVac plans a clinical trial for Rabies (Prevention) in early 2018
  • 11 Jan 2017 Interim efficacy data from the first-in-human phase I trial in Rabies (In volunteers, Prevention) released by CureVac
  • 11 May 2016 Phase I development is ongoing in Germany (Intradermal, needle-free injection & needle-based injection and IM, needle-based injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top